Please use this identifier to cite or link to this item:
http://hdl.handle.net/1942/36260
Title: | Aspirin-free antiplatelet regimens after PCI: insights from the GLOBAL LEADERS trial and beyond | Authors: | Wang, Rutao Wu, Sijing Gamal, Amr Gao, Chao Hara, Hironori Kawashima, Hideyuki Ono, Masafumi van Geuns, Robert-Jan VRANCKX, Pascal Windecker, Stephan Onuma, Yoshinobu Serruys, Patrick W. Garg, Scot |
Issue Date: | 2021 | Publisher: | OXFORD UNIV PRESS | Source: | EUROPEAN HEART JOURNAL-CARDIOVASCULAR PHARMACOTHERAPY, 7 (6) , p. 547 -556 | Abstract: | Historically, aspirin has been the primary treatment for the prevention of ischaemic events in patients with coronary artery disease. For patients undergoing percutaneous coronary intervention (PCI) standard treatment has been 12 months of dual antiplatelet therapy (DAPT) with aspirin and clopidogrel, followed by aspirin monotherapy; however, DAPT is undeniably associated with an increased risk of bleeding. For over a decade novel P2Y(12) inhibitors, which have increased specificity, potency, and efficacy have been available, prompting studies which have tested whether these newer agents can be used in aspirin-free antiplatelet regimens to augment clinical benefits in patients post-PCI. Among these studies, the GLOBAL LEADERS trial is the largest by cohort size, and so far has provided a wealth of evidence in a variety of clinical settings and patient groups. This article summarizes the state-of-the-art evidence obtained from the GLOBAL LEADERS and other trials of aspirin-free strategies. | Notes: | Serruys, PW (corresponding author), Imperial Coll London, Dept Cardiol, Exhibit Rd, London SW7 2BX, England. patrick.w.j.c.serruys@gmail.com |
Keywords: | Aspirin-free therapy; P2Y12 inhibitor; GLOBAL LEADERS; Randomized;clinical trials; Percutaneous coronary intervention | Document URI: | http://hdl.handle.net/1942/36260 | ISSN: | 2055-6837 | e-ISSN: | 2055-6845 | DOI: | 10.1093/ehjcvp/pvab035 | ISI #: | WOS:000720749900015 | Rights: | VC The Author(s) 2021. Published by Oxford University Press on behalf of the European Society of Cardiology. This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (http://creativecommons.org/licenses/by-nc/4.0/) | Category: | A1 | Type: | Journal Contribution | Validations: | ecoom 2022 |
Appears in Collections: | Research publications |
Files in This Item:
File | Description | Size | Format | |
---|---|---|---|---|
pvab035.pdf | Published version | 938.84 kB | Adobe PDF | View/Open |
Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.